efmoroctocog alfa at a glance
Medicine class
Recombinant, extended-half-life coagulation factor VIII
Licensed use
Treatment and prevention of bleeding in congenital haemophilia A
Who can use it
Licensed for all age groups
Administration
Injected into a vein after mixing the powder with the supplied solvent
What is efmoroctocog alfa used for?
It is licensed for people of any age with haemophilia A caused by congenital factor VIII deficiency.
Treating bleeding episodes
Preventing bleeding
Supporting haemostasis around surgery or invasive procedures as part of a specialist plan
How does efmoroctocog alfa work?
It replaces factor VIII, supporting clotting reactions that generate thrombin and fibrin at a bleeding site. Its factor VIII portion is joined to an immunoglobulin Fc region, which uses the neonatal Fc receptor recycling pathway to delay breakdown and extend circulation time.
efmoroctocog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 250 units, 500 units, 750 units, 1000 units, 1500 units, 2000 units, 3000 units, 4000 units
How to take efmoroctocog alfa
Use only as taught by the haemophilia team. Reconstitute the powder with the supplied water for injections, gently swirl without shaking, and inject the prepared solution into a vein using the supplied equipment.
Wash your hands and check the medicine name, vial and expiry date.
Let refrigerated components reach room temperature naturally; do not use external heat.
The solution should be clear to slightly opalescent and colourless. Do not use it if cloudy or if particles are visible.
Do not mix it with other injectable medicines or solutions.
Record the product name and batch number after each administration.
Food does not affect this intravenous treatment.
efmoroctocog alfa side effects
Common or expected effects
- Papular rash has been reported commonly in previously untreated patients.
- Device-related thrombosis has been reported commonly in previously untreated patients using venous access devices.
Get urgent medical advice
- Severe allergic reaction, including breathing difficulty, facial or throat swelling, widespread hives, low blood pressure or collapse.
- Factor VIII inhibitors, which may cause persistent bleeding or an unexpectedly poor response.
- Infection, bloodstream infection or thrombosis associated with a central venous access device.
efmoroctocog alfa in pregnancy
Experience during pregnancy is limited because haemophilia A is uncommon in women. Use only when clearly indicated following assessment by the haemophilia and maternity teams.
efmoroctocog alfa while breastfeeding
Evidence during breastfeeding is limited. Consider use only when clearly indicated after discussion with the specialist or prescriber.
efmoroctocog alfa interactions
No specific interactions with recombinant factor VIII have been reported, and formal interaction studies have not been performed. Other medicines may independently increase bleeding risk.
Aspirin and NSAIDs such as ibuprofen, naproxen or diclofenac
These can increase bleeding or bruising; check with the haemophilia team before use.
Anticoagulants such as warfarin, heparin, apixaban, rivaroxaban or dabigatran
These reduce clotting and may substantially increase bleeding risk, requiring specialist oversight.
Common questions about efmoroctocog alfa
Answers are fully visible for fast scanning and source review.
Is efmoroctocog alfa a factor VIII replacement?
Yes. It is a recombinant factor VIII Fc-fusion protein used to replace deficient factor VIII in haemophilia A.
Can it be used in children?
Yes. Its licence covers all age groups, with treatment managed by a specialist haemophilia team.
Can it be used at home?
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.